Pergamum AB Announces a Strategic Collaboration with Cadila Pharmaceuticals
News Feb 11, 2013
Pergamum AB and Cadila Pharmaceuticals Ltd have announced a strategic collaboration to develop a novel treatment of infections with a unique targeting mechanism clearly distinguished from classical antibiotics.
Pergamum is part of the Karolinska Development portfolio.
The two companies will collaborate on the preclinical and clinical development of a novel therapeutic peptide that has been developed by Pergamum AB.
The development will be conducted at the facilities of Cadila Pharmaceuticals Ltd in Ahmedabad, India.
Cadila will be responsible for all costs related to the development of the product up to Phase II and global rights will be shared between the companies.
Infections caused by resistant microorganisms often fail to respond to conventional treatment, resulting in prolonged illness and greater risk of death. There is a significant need for safe and effective new products to avoid infections.
"Pergamum has developed a new class of short synthetic peptides with both anti-infective and anti-inflammatory properties derived from the body’s own defense system. There is a rapidly increasing global prevalence of antibiotics resistance that limits the therapeutic value of conventional products, and we think that we can meet this need with this novel therapeutic peptide”, says Jonas Ekblom, CEO of Pergamum.
"This partnership combines Cadila’s advanced product development capabilities with the innovative capacity of Pergamum. Cadila Pharmaceuticals bring their expertise in drug development and demonstrates that commitment towards developing affordable innovative compounds to the market in this collaboration”, says Rajiv Modi, Chairman and Managing Director of Cadila Pharmaceuticals Ltd.
"We are delighted to see this collaboration between Cadila and Pergamum. This is a phenomenal opportunity for Pergamum to work with one of the largest pharmaceutical companies in India, a key emerging pharmaceutical market. The strategic value can be substantial for both parties”, commented Torbjörn Bjerke, CEO of Karolinska Development AB and Chairman of Pergamum AB.
The establishment of this cooperation was facilitated by Dr. CB Sanjeevi of Karolinska Institutet and Business Sweden.
Broadly Acting Antibodies Found in Blood of Ebola SurvivorsNews
Scientists have discovered a set of powerful, broadly neutralizing antibodies in the blood of Ebola survivors. In animal studies, two of these antibodies provided substantial protection against disease caused by the three species known to cause fatal human illness.READ MORE
Immatics Enters into a Strategic Partnership with GenmabNews
Immatics and Genmab to combine proprietary technologies to create transformative bispecific therapies against novel, proprietary tumor targets.READ MORE